Delivery Order SPE2DB22D1106-SPE2DB25FENA4
- Not listed
- The Defense Logistics Agency awarded a $50,978.64 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials. The award was made on September 11, 2025, with an ultimate completion date of October 2, 2025, and the product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order was competitively awarded with no set-aside designation and represents a continuation of the company's...
- The Defense Logistics Agency awarded a $26,285.93 delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 300 mg/3 mL vials on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed price contract contains no set-aside designation and identifies AmerisourceBergen's Conshohocken, Pennsylvania facility as the place of performance. The delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Ultomiris (pegtibatase alfa-ires) 1,100 mg/11 ml vials valued at $52,571.70 with a firm fixed price structure. This delivery order, awarded without set-aside designation through competitive procurement, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical valued at $999,999,999.00 and extending through...
- The U.S. Department of Defense Medical Supply Chain awarded AmerisourceBergen Drug Corp a delivery order valued at $102,754.09 for Ultomiris 300 mg/3 mL vials on September 15, 2025. This firm fixed-price, competitively awarded contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with the Defense Logistics Agency Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The delivery order is scheduled for...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $87,619.50 to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract is a firm fixed price delivery order with no set-aside designation, issued competitively on June 11, 2025, with an ultimate completion date of July 3, 2025. The place of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order...
- The U.S. Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Ultomiris (pegtibatimab alfa), a specialty pharmaceutical product, with a ceiling value of $26,285.85. This firm fixed-price delivery order is set to be completed by August 14, 2025, and represents performance at the vendor's corporate office location in Conshohocken, Pennsylvania. The award was competitively awarded with no set-aside designation,...
- The Defense Logistics Agency awarded a $131,429.25 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ultomiris (pegcetacoplan) 1,100 mg/11 mL vials. This contract, issued on August 15, 2025, with an ultimate completion date of September 8, 2025, represents a non-set-aside competitive award supporting federal pharmaceutical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for...
- The Defense Logistics Agency awarded a $9,558.52 firm fixed price delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Ultomiris 300 mg/3 ml vials. This non-competitive delivery order, with an ultimate completion date of September 29, 2025, represents a child contract under AmerisourceBergen's larger indefinite delivery contract with DLA Troop Support Medical. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $52,571.70 to AmerisourceBergen Drug Corp for the supply of Ultomiris (1,100 mg/11 mL vial), a pharmaceutical product for military healthcare needs. This is a firm fixed price, non-set-aside contract with an ultimate completion date of October 6, 2025, performed from the contractor's location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on June 6, 2025, for the supply of Ultomiris (periphakin alfa) 1,100 mg/11 ml vials under a firm fixed-price contract. The award, valued at $26,285.85 with a completion date of June 30, 2025, represents a non-competitive, non-set-aside delivery order issued by the Defense Logistics Agency's Medical Supply Chain. This contract is a child award under...
- SPE2DB22D1106Indefinite Delivery Contract
- SPE2DB22D1106-SPE2DB25FENA4Delivery Order
The Defense Logistics Agency awarded a $52,571.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Ultomiris (pegcetacoplan) 1,100 mg/11 ml vials on May 12, 2025, with an ultimate completion date of June 3, 2025. This non-set-aside contract represents a single delivery order under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company serves as a major pharmaceutical distributor for federal medical procurement. This delivery order is issued under AmerisourceBergen's comprehensive pharmaceutical prime vendor contract that supplies critical medical commodities to support military healthcare programs worldwide. Ultomiris is a specialty pharmaceutical product used for treatment of complement-mediated diseases, reflecting the company's role in providing brand-name and specialized medications across multiple therapeutic domains to the Defense Health Agency and other federal healthcare systems. The firm fixed-price structure and competitive award history demonstrate AmerisourceBergen's established capability to fulfill federal medical supply requirements efficiently through the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $52.6k | 5/12/25 |